Consulting Report

Shah, K., Chapman, A., Devlin, N. and Barnsley, P.

Consulting Report
February 2015

Stated preference studies are increasingly being used to understand people’s views about the relative importance of different criteria for making health care priority setting decisions.

Rejon-Parrilla, J.C., Garau, M. and Sussex, J.

Consulting Report
September 2014

Obstructive sleep apnoea (OSA) is the temporary cessation of breathing during sleep because of a narrowing or closure of the pharyngeal airway. Untreated OSA can result in daytime sleepiness that affects cognitive function, mood and quality of life and can increase the risks of road traffic, work-related accidents and cardiovascular disease and strokes.

Lewis, F., Karlsberg Schaffer, S., Sussex, J., O'Neill, P. and Cockcroft, L.

Consulting Report
June 2014

Alzheimer’s Research UK commissioned OHE Consulting to model the incidence and cost of dementia in the UK and the potential impact of better treatment. The analyses estimate the extent of the substantial reductions in health and social care costs that are possible to 2050.

Rejon-Parrilla, J.C., Hernandez-Villafuerte, K., Shah, K., Mestre-Ferrandiz, J., Garrison, L. and Towse, A.

Consulting Report
May 2014

This report examines the importance and history of HTA evaluations for additional uses for cancer drugs after their initial approval. Included are the ten cancer drugs approved by the EMA during 2003–2005. Decisions by France’s HAS, NICE and Aetna in the US are analysed.

This study was intended to identify and analyse inefficiencies and bottlenecks that undermine health systems' sustainability and potential policy solutions to tackle them.

Consulting

Founded in 2002, OHE Consulting
provides client-focused, specialised
expertise on policy and strategic issues
affecting the delivery of health care
and the future of the pharmaceutical
and life sciences industries
.

We are dedicated to providing objective,
independent advice to help
our clients achieve their objectives.

O’Neill, P., Puig-Peiro, R., Mestre-Ferrandiz, J. and Sussex, J.

Consulting Report
October 2012

Since 1996, in its yearly PPRS Report to Parliament, the Department of Health in England has published international price comparisons of branded medicines used in the primary care setting. OHE Consulting uses the same methodology in this report to update comparisons through 2011.

Mestre-Ferrandiz, J., Mordoh, A. and Sussex, J.

Consulting Report
June 2012

This report provides a clear explanation of the nature of innovation in medicines.  A fully revised and expanded version of the 2005 edition, it updates the literature review of the economics of innovation, traces important innovation that has occurred since 2005, adds new case studies and updates the discussion of competition in pharmaceutical R&D.

O'Neill, P., Devlin, N. and Puig-Peiro, R.

Consulting Report
January 2012

According to the 1999 UK Department of Health consultation document, the fundamental purpose of the National Institute for Health and Clinical Excellence (NICE) was to reduce inequalities in access to innovative care and ensure more rapid access to medicines identified as being of value to the NHS. Since NICE’s debut in April 1999, several analyses have examined the uptake of technologies that have been considered by NICE, but no evidence has yet been published on whether and how NICE’s health technology appraisal (HTA) processes may have affected the speed of access to new treatments.

Baillie, L., Hawe, E., O'Neill, P. and Greville, R.

Consulting Report
November 2011

In this, report commissioned by the ABPI in Wales, OHE Consulting examines the use of medicines in primary care in Wales since 2000 compared to the other countries of the UK.

Pages

Subscribe to RSS - Consulting Report